Skip to main content

Table 1 Tumour and normal tissue biodistribution (BOD) of radioimmunoconjugates in NRG mice with s.c. HNSCC primary xenografts a

From: Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

 

[64Cu]Cu-DOTA-panitumumab F(ab´)2

 

[177Lu]Lu-DOTA-panitumumab F(ab´)2

[177Lu]Lu-DOTA-trastuzumab F(ab’)2

      

Percent injected dose/g (%ID/g)

Time p.i.:

6 h

P-

value b

24 h

P-value b

P-value c

48 h

P-value b

6 h

24 h

P-value c

48 h

24 h

Heart

3.5 ± 0.5

n.s.

2.8 ± 0.3

n.s.

0.04

1.5 ± 0.1

n.s.

4.4 ± 0.2

2.9 ± 0.05

0.04

1.5 ± 0.5

1.3 ± 0.2

Lungs

3.9 ± 0.2

n.s.

3.4 ± 0.2

n.s.

0.04

2.4 ± 0.0

0.03

5.2 ± 0.6

2.1 ± 0.3

0.04

1.3 ± 0.0

1. 1 ± 0.1

Stomach

1.5 ± 0.1

n.s.

1.8 ± 0.1

n.s.

0.04

1.5 ± 0.1

0.03

1.8 ± 0.1

1.4 ± 0.0

0.04

0.8 ± 0.1

0.4 ± 0.05

Pancreas

1.0 ± 0.1

n.s.

1.2 ± 0.2

n.s.

n.s.

1.2 ± 0.2

0.03

1.2 ± 0.2

1.0 ± 0.1

n.s.

0.6 ± 0.1

0.5 ± 0.2

Intestine

1.2 ± 0.0

n.s.

1.7 ± 0.1

n.s.

0.04

1.5 ± 0.1

0.03

1.9 ± 0.1

1.3 ± 0.1

0.04

1.0 ± 0.1

0.4 ± 0.07

Spleen

2.4 ± 0.1

n.s.

3.5 ± 0.3

n.s.

n.s.

4.0 ± 0.7

n.s.

3.3 ± 0.1

4.3 ± 0.6

n.s.

3.8 ± 0.4

5.9 ± 1.4

Liver

8.4 ± 0.8

n.s.

7.5 ± 1.0

n.s.

n.s.

6.2 ± 0.1

0.03

10.1 ± 1.6

12.1 ± 1.1

0.04

11.0 ± 0.9

8.0 ± 1.0

Kidneys

5.5 ± 0.2

n.s.

4.7 ± 0.5

n.s.

0.04

3.0 ± 0.2

n.s.

8.1 ± 0.5

5.9 ± 0.0

0.04

4.1 ± 0.4

27.4 ± 2.7

Bone

1.0 ± 0.3

n.s.

0.6 ± 0.1

n.s.

n.s.

0.6 ± 0.1

n.s.

1.2 ± 0.1

1.8 ± 0.7

n.s.

0.6 ± 0.0

2.6 ± 1.6

Skin

1.0 ± 0.3

n.s.

2.7 ± 1.2

n.s.

n.s.

1.0 ± 0.1

0.03

2.0 ± 0.3

2.2 ± 0.7

n.s.

1.6 ± 0.1

0.9 ± 0.2

Muscle

0.6 ± 0.1

n.s.

0.4 ± 0.1

n.s.

n.s.

0.4 ± 0.0

0.03

0.7 ± 0.1

0.6 ± 0.1

n.s.

0.5 ± 0.0

0.3 ± 0.07

Blood

10.6 ± 0.6

n.s.

4.8 ± 0.3

n.s.

0.04

1.9 ± 0.1

0.03

15.3 ± 0.6

4.5 ± 0.1

0.04

1.1 ± 0.2

1.3 ± 0.3

Tumour

9.3 ± 1.0

n.s.

14.9 ± 1.1

n.s.

0.04

9.8 ± 1.3

n.s.

10.4 ± 2.0

18.0 ± 0.4

0.04

15.3 ± 2.6

2.6 ± 0.5

T/B Ratio d

0.9 ± 0.1

n.s.

3.1 ± 0.1

n.s.

n.s.

5.1 ± 0.8

0.03

0.7 ± 0.1

4.0 ± 0.1

n.s.

14.7 ± 2.8

2.2 ± 0.6

  1. a[64Cu]Cu-DOTA-panitumumab F(ab´)2 (5.5–14.0 MBq; 50 μg) or [177Lu]Lu-DOTA-panitumumab F(ab´)2 (6.5 MBq; 50 μg) were injected i.v. (tail vein) in groups (n = 3–4) of tumour-bearing NRG mice
  2. bP-value for comparison of [64Cu]Cu-DOTA-panitumumab F(ab´)2 and [177Lu]Lu-DOTA-panitumumab F(ab´)2 at the same time point (6, 24 or 48 h) post-injection using a Mann-Whitney U test
  3. cP-value for comparison of [64Cu]Cu-DOTA-panitumumab F(ab´)2 or [177Lu]Lu-DOTA-panitumumab F(ab´)2 to [177Lu]Lu-DOTA-trastuzumab F(ab´)2 at 24 h p.i. using a Mann-Whitney U test
  4. dT/B: tumour:blood